Spero Therapeutics Inc (SPRO) Expected to Announce Earnings of -$0.76 Per Share

Share on StockTwits

Wall Street analysts predict that Spero Therapeutics Inc (NASDAQ:SPRO) will post ($0.76) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Spero Therapeutics’ earnings. The lowest EPS estimate is ($0.96) and the highest is ($0.61). Spero Therapeutics posted earnings per share of ($1.59) in the same quarter last year, which would indicate a positive year-over-year growth rate of 52.2%. The business is scheduled to issue its next earnings results on Monday, April 1st.

On average, analysts expect that Spero Therapeutics will report full-year earnings of ($2.81) per share for the current year, with EPS estimates ranging from ($3.01) to ($2.62). For the next financial year, analysts expect that the business will post earnings of ($3.35) per share, with EPS estimates ranging from ($4.08) to ($2.59). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Spero Therapeutics.

Several brokerages recently weighed in on SPRO. Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a research note on Monday, February 4th. They issued a “buy” rating and a $27.00 price objective on the stock. Zacks Investment Research cut shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 18th. Oppenheimer set a $30.00 price objective on shares of Spero Therapeutics and gave the stock a “buy” rating in a research note on Sunday, January 13th. Finally, ValuEngine cut shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $20.65.

Shares of Spero Therapeutics stock opened at $10.16 on Thursday. Spero Therapeutics has a twelve month low of $5.52 and a twelve month high of $19.00. The firm has a market capitalization of $174.64 million, a P/E ratio of -0.57 and a beta of 2.94.

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in Spero Therapeutics by 4.4% in the fourth quarter. Geode Capital Management LLC now owns 91,842 shares of the company’s stock valued at $564,000 after buying an additional 3,876 shares during the period. Northern Trust Corp lifted its holdings in Spero Therapeutics by 1.1% in the fourth quarter. Northern Trust Corp now owns 96,833 shares of the company’s stock valued at $595,000 after buying an additional 1,038 shares during the period. Bank of New York Mellon Corp lifted its holdings in Spero Therapeutics by 31.9% in the fourth quarter. Bank of New York Mellon Corp now owns 36,716 shares of the company’s stock valued at $226,000 after buying an additional 8,888 shares during the period. BlackRock Inc. lifted its holdings in Spero Therapeutics by 5.7% in the fourth quarter. BlackRock Inc. now owns 393,630 shares of the company’s stock valued at $2,421,000 after buying an additional 21,161 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in Spero Therapeutics by 58.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 15,800 shares of the company’s stock valued at $98,000 after buying an additional 5,800 shares during the period. Institutional investors and hedge funds own 56.94% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Read More: The components of the Stochastic Momentum Index

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply